2 Immunotherapies Show Comparable Benefits in Extensive-Stage Small Cell Lung Cancer
“Key Takeaways: PD-1 and PD-L1 inhibitors combined with chemotherapy significantly improve survival in ES-SCLC compared with chemotherapy alone. No significant difference in overall survival or progression-free survival was found between PD-1 and PD-L1 inhibitors.”
FDA Grants Fast Track Designation to IBI363 for Squamous NSCLC
“Key Takeaways: IBI363 received FDA fast track designation for squamous NSCLC after prior anti–PD-(L)1 therapy and chemotherapy. Phase 1 trial data showed a 50% ORR and 88.9% DCR at a 3-mg/kg dose, with median PFS not reached.”
‘Off-Grid’ Electrical Activity Drives Tumor Growth in Small Cell Lung Cancer
“Researchers from the Francis Crick Institute in London discovered aggressive lung cancer cells capable of forming their own electrical network, much like the body’s own nervous system. The findings, published in Nature, suggest that this property could make lung cancer cells less dependent on the environment surrounding tumors, allowing them to spread more easily around the body.”
Lung Cancer Is Rising in Non-Smokers, And This Could Be Why
“While the number of smokers in the world as a proportion of the population is dropping, lung cancer continues to cause almost 2 million deaths per year – and new research reports on a concerning rise in cases among people who’ve never lit up a cigarette.”
DNA’s organization influences the risk of smoking-induced lung cancer
“The study from The Hebrew University of Jerusalem, led by Prof. Sheera Adar and her graduate student Elisheva Heilbrun-Katz from The Institute for Medical Research Israel-Canada in the Faculty of Medicine in collaboration with Prof. Raluca Gordan from Duke University and the University of Massachusetts, has uncovered how the structure and chemical modifications of DNA affect the damage caused by cigarette smoke and the body’s ability to repair it. This breakthrough helps explain how smoking leads to lung cancer.”
Lung lesion volume doubling times associated with survival metrics
“The takeaway? Volume doubling time is “widely accepted as a key indicator of the growth rate of lung nodules, reflecting biologic aggressiveness and prognosis for those nodules corresponding with cancer,” the group wrote. “For part-solid lesions, volume doubling time of the solid component may be expected to have greater prognostic utility than volume doubling time of the whole lesion, given the greater association of the solid component than ground-glass component of such lesions with pathologically invasive cancer.””
Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer
“AUSTIN, Texas, Feb. 13, 2025 /PRNewswire/ — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators at a major cancer research center in Houston, Texas have published a new study in eLife titled, “NPRL2 gene therapy induces effective antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic non-small cell lung cancer (NSCLC) in a humanized mouse model.””
New Study May Lead to More Personalizing Lung Cancer Treatments
“Dr. Momcilovic’s goal is to develop better, personalized treatments for lung cancer by understanding each patient’s unique tumor characteristics and finding the right therapy for them. She hopes to figure out why some treatments work for certain patients but not others, identify biomarkers that can predict which treatments will work, and discover new combination therapies that might be more effective than current standard-of-care treatments.”
Cancer’s ripple effect may promote blood clots in lungs
“Blood clots form in response to signals from the lungs of cancer patients – not from other organ sites, as previously thought – according to a preclinical study by Weill Cornell Medicine, Memorial Sloan Kettering Cancer Center and University of California San Diego Health.”
